ARCH's reduction from 7.4% to 6.9% and explicit disavowal of activist plans signals a passive posture. Monitor whether further selling continues below the 5% threshold, which would eliminate the 13D filing requirement and reduce overhang.
VIR drugs
VIR drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $13.65entry
- T+1 · 7d ago −3.63%α −3.26% · $13.15
- T+5 · 18h ago −29.79%α −28.10% · $9.58
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
ARCH Venture Fund IX and affiliates sold 796,175 shares of Vir Biotechnology over November 3-5, 2026, reducing their aggregate beneficial ownership from 7.4% to 6.9% (based on 171.3M shares outstanding). The filing states no current plans for board changes, extraordinary transactions, or other control-related actions, marking a de-escalation from prior activist positioning.
Key Financial Metrics
Key Facts
- ARCH Venture Fund IX and ARCH Venture Fund IX Overage sold a combined 796,175 shares of Vir Biotechnology common stock from November 3-5, 2026.
- Weighted average sale prices ranged from $11.24 to $12.06 per share across four trading days.
- Aggregate beneficial ownership of the ARCH reporting persons decreased to 6.9% from 7.4% in the prior filing.
- The filing explicitly states no present plans for board changes, mergers, asset sales, or other extraordinary transactions.
- The sale occurred just two days after Vir's Q3 2026 earnings release (November 4, 2026) which reported a narrower net loss of $96.3M.
Financial Impact
ARCH sold 796,175 shares at approximately $11.24-$12.06 per share, representing about 0.5% of shares outstanding.
Risk Factors
- Continued selling by ARCH could further pressure the stock.
- ARCH's exit below 5% would remove a major supportive shareholder and reduce public scrutiny.
- No activist catalysts remain; stock direction depends solely on pipeline data (Phase 3 ECLIPSE 1 results expected Q4 2026).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13D/A Filing (Primary) | 0001012975-26-001020 |
| Document: 0001012975-26-001020-index.html | 0001012975-26-001020 |
| Document: 0001012975-26-001020.txt | 0001012975-26-001020 |
Track record
36 reports on VIR
3 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +26.32% at T+20 after the Oct 14, 2026 report. 4 of 8 went positive at some point.
Filters
- Nov 16, 2026today 424B5 Bearish 5/10 Entry $9.84 Now $9.58 +2.64% settles Nov 23
- Nov 13, 20263d ago 8-K Bearish 5/10 Entry $9.92 Now $9.58 +3.43% settles Nov 23
- Nov 12, 20264d ago 424B5 Bearish 5/10 Entry $9.96 Now $9.58 +3.82% settles Nov 20
- Nov 12, 20264d ago S-3ASR Neutral 3/10 Entry $9.96 Now $9.58 −3.82% settles Nov 20
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $13.15 Now $9.58 −27.15% settles Nov 17
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $13.65 to $9.58 Now $9.58 −29.79% ▼ −29.79% −28.10% vs SPY
- Nov 6, 202610d ago SC 13D/A Bearish 5/10 Viewing Entry $13.65 to $9.58 Now $9.58 +29.79% ▲ +29.79% +28.10% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $11.02 to $12.12 Now $9.58 −13.07% ▲ +9.98% +6.69% vs SPY
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $11.22 to $13.15 Now $9.58 −14.62% ▲ +17.20% +17.79% vs SPY
- Nov 2, 202614d ago 144 Neutral 1/10 Entry $11.00 to $13.65 Now $9.58 −12.91% ▲ +24.05% +23.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers